MedTrace Logo

Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression

NCT00134784 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2014-08-08

Study results available
· View outcomes & findings →

Summary

The purpose of this project is to assess the change in dopamine transporter density in Parkinson's disease subjects during a sixty month period including a nine month treatment trial of levodopa. Dopamine transporter will be assessed using \[123I\]ß-CIT SPECT (single photon emission computed tomography) imaging, a marker of dopamine terminal integrity and of clinical disease state.

Conditions

  • Parkinson Disease

Interventions

DRUG

[123I]B-CIT SPECT imaging

To assess \[123I\]B-CIT SPECT imaging

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Institute for Neurodegenerative Disorders

    lead OTHER

Principal Investigators

  • Kenneth L Marek, MD · Institute for Neurodegenerative Disorders

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-04-30
Primary Completion
2007-05-31
Completion
2007-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00134784 on ClinicalTrials.gov